EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Effects of In-House Cryoprecipitate Use on Transfusion Volume for Cardiopulmonary Bypass Surgery

Wakana Niwa, Yoshiyuki Takami, Atsuo Maekawa, Koji Yamana, Kiyotoshi Akita, Kentaro Amano, Kazuki Matsuhashi, Yasushi Takagi, Tomonobu Abe

Annals of Thoracic and Cardiovascular Surgery · 2025

DOI: 10.5761/atcs.oa.25-00166 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of Thoracic and Cardiovascular Surgery, 2025. Verfasst von Wakana Niwa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, Fujita Health University School of Medicine, Toyoake, Aichi, Japan. Hauptthemen laut MEDLINE: Cardiopulmonary Bypass, Fibrinogen, Factor VIII, Blood Transfusion. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Cryoprecipitate has been covered by Japanese national health insurance since 2020 for cardiopulmonary bypass (CPB)-induced hypofibrinogenemia. This study evaluated the clinical efficacy of in-house cryoprecipitate use in patients undergoing CPB. METHODS: A total of 1357 patients were divided into 2 groups before and after cryoprecipitate introduction in February 2020 (Group A, n = 685; Group B, n = 672). Propensity score matching also compared 205 pairs between transfused patients in Group A (Group A', n = 597) and those receiving cryoprecipitate in Group B (Group B', n = 222). RESULTS: Cryoprecipitate was used in 222 patients (37%) in Group B. While overall transfusion rates did not differ significantly, postoperative red blood cell (20% vs 13%, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiopulmonary BypassFibrinogenFactor VIIIBlood TransfusionBlood Loss, SurgicalPostoperative HemorrhageHumansMaleFemaleMiddle AgedAgedTreatment OutcomeRetrospective StudiesRisk FactorsTime Factors

Stichwörter der Autor:innen

blood transfusioncardiopulmonary bypasscryoprecipitatefibrinogen

Substanzen

Fibrinogencryoprecipitate coagulumFactor VIII

Autor:innen und Institutionen

  • Department of Cardiac Surgery, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.

Zitieren

APA

Niwa, W., Takami, Y., Maekawa, A., Yamana, K., Akita, K., Amano, K., Matsuhashi, K., Takagi, Y., & Abe, T. (2025). Effects of In-House Cryoprecipitate Use on Transfusion Volume for Cardiopulmonary Bypass Surgery. Annals of Thoracic and Cardiovascular Surgery. https://doi.org/10.5761/atcs.oa.25-00166

Vancouver

Niwa W, Takami Y, Maekawa A, Yamana K, Akita K, Amano K, et al. Effects of In-House Cryoprecipitate Use on Transfusion Volume for Cardiopulmonary Bypass Surgery. Annals of Thoracic and Cardiovascular Surgery. 2025. doi:10.5761/atcs.oa.25-00166

BibTeX
@article{Niwa2025,
  author = {Niwa, Wakana and Takami, Yoshiyuki and Maekawa, Atsuo and Yamana, Koji and Akita, Kiyotoshi and Amano, Kentaro and Matsuhashi, Kazuki and Takagi, Yasushi and Abe, Tomonobu},
  title = {Effects of In-House Cryoprecipitate Use on Transfusion Volume for Cardiopulmonary Bypass Surgery},
  journal = {Annals of Thoracic and Cardiovascular Surgery},
  year = {2025},
  doi = {10.5761/atcs.oa.25-00166}
}
Kostenlos starten →